(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 70.11% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Liquidia's revenue in 2026 is $288,065,000.On average, 9 Wall Street analysts forecast LQDA's revenue for 2026 to be $65,021,558,146, with the lowest LQDA revenue forecast at $51,115,871,305, and the highest LQDA revenue forecast at $71,991,742,545. On average, 9 Wall Street analysts forecast LQDA's revenue for 2027 to be $103,156,594,840, with the lowest LQDA revenue forecast at $76,592,882,388, and the highest LQDA revenue forecast at $131,524,658,421.
In 2028, LQDA is forecast to generate $122,187,208,026 in revenue, with the lowest revenue forecast at $98,888,046,088 and the highest revenue forecast at $141,395,677,410.